Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on November 8, 2021. The filing serves to announce the Company's financial results for the third quarter ended September 30, 2021. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol CARA.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that the Company issued a press release announcing Q3 2021 results.
Guidance, Outlook, and Risks
The text does not contain management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information furnished pursuant to Item 2.02 (including the press release) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific Q3 2021 financial figures (revenue, net loss, cash position) in the press release attached as Exhibit 99.1.
- Confirm the Company name is Cara Therapeutics, Inc. (the input metadata incorrectly listed "Tvardi Therapeutics, Inc.").
- Review the full press release for any updates on clinical trial progress or regulatory milestones not detailed in this 8-K summary.
- Note that the financial data in the referenced press release is not legally "filed" under Section 18 of the Exchange Act per the language in this document.